News
With the IDE approval, Presidio will initiate a pivotal trial of its neuromodulation platform in treating nociceptive low ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback